third-news.com
Beactica Therapeutics Kicks Off IND-Enabling Studies for First-in-Class Glioblastoma Drug BEA-17
Beactica Therapeutics has commenced IND-enabling studies for BEA-17, a groundbreaking treatment aimed at improving glioblastoma outcomes through innovative mechanisms.